Sales of Novo Nordisk’s oral weight-loss drug Rybelsus have plateaued as Indians increasingly shift to injectable GLP-1 drugs like Eli Lilly’s Mounjaro, which has captured ₹450 crore in seven months. Injectables offer higher efficacy and convenience, though experts expect orals to rebound once higher-dose, cheaper versions launch post-2026.